CoChat

Process intensification in the biopharma industry: Improving efficiency of protein manufacturing processes from development to production scale using synergistic approaches

Open access
Müller, Dirk, Klein, Lukas, Lemke, Johannes, Schulze, Markus, Kruse, Thomas, Saballus, Martin, Matuszczyk, Jens, Kampmann, Markus, Zijlstra, Gerben · 2022 · Chemical Engineering and Processing - Process Intensification
Cited by 75

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Process intensification strives for more efficient conversion of raw materials into products while minimizing resource usage. In the biopharma industry, typical intensification gains include increased plant capacities, reduced raw material costs, smaller facilities and improved sustainability. Rapid growth combined with increasingly diverse and challenging molecule formats in the biopharma sector necessitate strategies for fast development of highly productive and cost-efficient processes. Using monoclonal antibody production in CHO cells as example, we present intensification techniques and process sequences that deliver synergistic benefits like increasing space-time yields up to 10-fold, shortening production runs by 30%, or saving numerous days in cell expansion. Combining highly productive perfusion with continuous downstream purification promises improved yields and production economics, especially for advanced, often labile molecules. Predictive scale-down models demonstrated here for selecting intensification-ready cell lines and for rapid setup of intensified processes are essential to realize such benefits broadly in the industry. They enable testing and quick tailoring of intensification alternatives like high-inoculation fed-batch or perfusion to suit molecule needs, facility space, and financial conditions. Since many techniques also readily extend to other protein biotherapeutics, intensification can be regarded as key pillar enabling fast, cost-efficient development and production of biopharma products in the coming years.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cep.2021.108727

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 75

Metadata

Authors
Müller, D., Klein, L., Lemke, J., Schulze, M., Kruse, T., Saballus, M., Matuszczyk, J., Kampmann, M., & Zijlstra, G.
Venue
Chemical Engineering and Processing - Process Intensification
Publisher
Elsevier BV
Published
2022-01
Volume
171
Pages
108727
ISSN
0255-2701 (ISSN-L)
OpenAlex
W3212611295
Cited by
75
References
4
FWCI
2.88
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Process intensification in the biopharma industry: Improving efficiency of protein manufacturing processes from development to production scale using synergistic approaches. https://app.cochat.ai/papers/10.1016/j.cep.2021.108727
The paper
Müller, D., Klein, L., Lemke, J., Schulze, M., Kruse, T., Saballus, M., Matuszczyk, J., Kampmann, M., & Zijlstra, G. (2022). Process intensification in the biopharma industry: Improving efficiency of protein manufacturing processes from development to production scale using synergistic approaches. Chemical Engineering and Processing - Process Intensification. https://doi.org/10.1016/j.cep.2021.108727

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.